N/A N=258 In-Office Study of the Hummingbird® in Children 6 Months-21 Years Old
Ear Infection · Otitis Media
Primary: Rate of Ears Experiencing an Adverse Events From Enrollment to 3-10 Week Follow-up — 0.41 percentage of ears
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=224 Study Evaluating the Safety and Efficacy of NCX 4251 Ophthalmic Suspension for the Treatment of Blepharitis
Blepharitis
Primary: Percentage of Study Eyes With Complete Cure (Score 0) of Blepharitis Signs and Symptoms at Day 15 — 4; 2 study eyes — p=0.4434
N/A N=166 SPREAD-NET: PRactices Enabling Adapting and Disseminating in the Safety NET
Diabetes Mellitus · Cardiovascular Disease
Primary: Rate Ratio of the Percent of the Clinics' Patients "Indicated" for Statin With a Guideline-appropriate Prescription for Statins — 1.09; 1.11; 1.06; 1.04 Rate ratio
N/A N=2 Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease
Multiple Myeloma · Amyloidosis
Primary: Number of Participants Without Renal Allograft Rejection at 6 Months Post-transplant — 1 Participants
Phase 3 N=26 Time Course of Response to Methylphenidate HCl ER Capsules in Children 6 to 12 Years With ADHD in Classroom Setting
Attention Deficit Hyperactivity Disorder · ADHD
Primary: Comparison Following Treatment Between Drug and Placebo Using Evaluation by SKAMP Combined, Attention, and Deportment Scales — 1.46; 2.03 units on a scale — p=<0.01
Phase 4 N=40 Namenda (Memantine) for Non-motor Symptoms in Parkinson's Disease
Parkinson's Disease
Primary: Unified Parkinson Disease Rating Scale (UPDRS). — 12; 12; 10; 10 units on a scale
Phase 2 N=30 Donor-Derived Viral Specific T-cells (VSTs) for Prophylaxis Against Viral Infections After Allogeneic Stem Cell Transplant
Allogeneic Stem Cell Transplant · Viral Infection
Primary: Number of Participants With Presence of a Toxicity — 0 Participants
Phase 4 N=20 Mechanisms of Belatacept Effect on Alloimmunity and Antiviral Response After Kidney Transplantation (BMS IM 103-309)
Renal Transplant Rejection
Primary: Antibody and T Cell-mediated Immune Response — 17; 0; 0; 1 participants
Phase 2 N=12 A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS)
Sjögren-Larsson Syndrome
Primary: Number of Participants Experiencing a Serious Adverse Event (SAE). — 0; 0 Participants
Phase 2 N=21 Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Advanced Malignant Solid Neoplasm · Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma · Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma
Primary: Response Rate — 0 Percentage of patients
Phase 2 N=306 Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine
Influenza Immunization · Healthy Volunteers
Primary: Number of Participants With Immediate Unsolicited Adverse Events (AEs) — 1; 1; 0 Participants
Phase 2 N=20 Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy
Polypoidal Choroidal Vasculopathy
Primary: Incidence and Severity of Ocular and Systemic Adverse Events Will be Compared Between the 2.0mg or 1.0mg (HIGH DOSE) and 0.5 mg Groups. — 4; 24; 0; 6 Adverse events…
N/A N=10 A Study to Assess the Tolerability and Efficacy of AKST1210 in Patients on Hemodialysis With Cognitive Impairment
Cognitive Impairment · End Stage Renal Disease
Primary: Number of Participants With Treatment-Emergent Adverse Events Assessed by Intensity — 0; 1; 2; 2 participants
Phase 3 N=151 Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)
Neurodermatitis
Primary: Percentage of Participants With Improvement (Reduction) in Worst Itch Numeric Rating Scale (WI-NRS) Scores by Greater Than or Equal to (>=) 4 Points From Baseline to…
N/A N=64 Weight Loss for Prediabetes Using Episodic Future Thinking
PreDiabetes
Primary: Change From Baseline in Delay Discounting — -5.92; -6.11; -3.09; -0.96 ln (k) — p=0.0035